SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Ionis and Novartis heart drug fails late-stage main goal

Ionis Pharmaceuticals and partner Novartis said their experimental drug aimed at lowering high levels of a fat-and-protein particle in heart patients missed the main goal in a late-stage trial.

IONSNOT

Story updates

09:19:24 PM UTC
SquawkNews
Ionis Pharmaceuticals NASDAQ:IONS and partner Novartis' BX:NOT experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.Shares of Ionis fell 6% in aftermarket trading.The drug, pelacarsen, did not meet the…

Ionis Pharmaceuticals NASDAQ:IONS and partner Novartis' BX:NOT experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.Shares of Ionis fell 6% in aftermarket trading.The drug, pelacarsen, did not meet the…